|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
Hsp90 is one of the most important chaperones involved in regulating the maturation of more than 300 client proteins, many of which are closely associated with refractory diseases, including cancer, neurodegenerative diseases, and viral infections.
|
31663736 |
2020 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, small molecules that inhibit the HSP90 but also increase the HSP70 has been tested as potential drugs for neurodegenerative disorders.
|
31816334 |
2020 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
Hsp90 is not only critical for routine protein maintenance in healthy cells, but also during states of cellular stress, such as cancer and neurodegenerative diseases.
|
31793427 |
2019 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
Brain Aging: Hsp90 and Neurodegenerative Diseases.
|
30232754 |
2019 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review we summarize results regarding the role of Hsp90 and its co-chaperones in neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and prionopathies.
|
31600883 |
2019 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein, we discuss the broad understanding of many Hsp90/Cdc37 pathways and how this protein complex may be a useful target to regulate the progression of neurodegenerative disease.
|
31824256 |
2019 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
Hsp90 has emerged as a key chemotherapeutic target for the development of drugs for the treatment of cancer and neurodegenerative diseases.
|
29177653 |
2018 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
Heat shock protein 90 (Hsp90) is a chaperone under investigation for the treatment of cancer and neurodegenerative diseases.
|
29137866 |
2018 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
Conversely, HSP90, and its secreted forms, contribute to the development and progress of serious pathologies, including cancer and neurodegenerative diseases.
|
30158430 |
2018 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we will discuss the role of intracellular and extracellular STI1 and the Hsp70/Hsp90 chaperone network in mechanisms underlying protein misfolding in neurodegenerative diseases, with particular focus on AD.
|
28559789 |
2017 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
As HSP90 has several hundred protein substrates (or 'clients'), it is involved in many cellular processes beyond protein folding, which include DNA repair, development, the immune response and neurodegenerative disease.
|
28429788 |
2017 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
This review highlights the current understanding of how the Hsp90 family of molecular chaperones regulates tau or other misfolded proteins in neurodegenerative diseases with a particular emphasis on the impact of aging.
|
29311797 |
2017 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
This quality makes the HSP90 an ideal candidate for novel inhibitory target for therapeutic modality in NDs.
|
28758577 |
2017 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
Heat Shock Protein 90 (Hsp90) is a molecular chaperone under clinical investigation for the treatment of neurodegenerative diseases and cancer.
|
28844386 |
2017 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
Induction of neuroprotective heat-shock proteins via pharmacological Hsp90 inhibitors is currently being investigated as a potential treatment for neurodegenerative diseases.
|
27457810 |
2017 |
|
HSP90AA1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The Hsp70, as a protein stabilizer, has a cellular protection against neurodegeneration of the central nervous system, while Hsp90 promote neurodegenerative disorders indirectly through regulating the expression of Hsp70 and other chaperones.
|
25147790 |
2014 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
Heat-shock protein 90 (HSP90) is a promising druggable target for therapy of conditions including cancer, renal disease, and chronic neurodegenerative diseases.
|
25308700 |
2014 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
Hsp90 inhibition has shown promising outcomes in some neurodegenerative diseases, but nothing is known about its effects in MJD.
|
24477711 |
2014 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
The results identify important roles played by Hsp90 in maintaining and facilitating the degenerative phenotype in these diseases and provide a common principle governing cancer and neurodegenerative diseases.
|
17517623 |
2007 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
The ability of 17-AAG to degrade mutant protein would be directly applicable to SBMA and other neurodegenerative diseases in which the disease-causing proteins also belong to the Hsp90 client protein family.
|
17185503 |
2006 |
|
HSP90AA1
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results indicate that inhibition of the hsp90-dependent trafficking mechanism prevents aggregation of the expanded glutamine androgen receptor, thereby opening a variety of novel therapeutic approaches to these neurodegenerative disorders.
|
16644868 |
2006 |